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        More than 100,000 squamous cell carcinomas 
(SCCs) of the skin are diagnosed each year in 
the United States (  1  ). Nonmelanoma skin can-
cer, of which SCC is the second most frequent 
type, is the fi  fth most costly cancer, accounting 
for 4.5% of all Medicare cancer costs (  2  ). The 
premalignant precursors to SCC, actinic kera-
toses, are the third most frequent reason in the 
United States for consulting a dermatologist (  3  ). 
More than 5.2 million physician visits are made 
each year for the treatment of actinic keratoses 
at a cost of more than 900 million dollars annu-
ally (  4  ). 
  Solid organ transplant recipients on immuno-
suppressive medications frequently develop mul-
tiple and aggressive SCCs (  5  ). These individuals 
have a 65  –  250-fold increased risk of SCCs, nearly 
10% of these tumors metastasize, and the major-
ity of these patients die as a result (  5, 6  ). The 
development of SCCs in transplant recipients is 
linked to the use of medications that suppress 
T cell activity (  6  ). T cell function therefore 
appears critical to the immunological control of 
SCCs. We present our fi  ndings that SCCs from 
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  Squamous cell carcinomas (SCCs) of the skin are sun-induced skin cancers that are particu-
larly numerous in patients on T cell immunosuppression. We found that blood vessels in 
SCCs did not express E-selectin, and tumors contained few cutaneous lymphocyte antigen 
(CLA)  +   T cells, the cell type thought to provide cutaneous immunosurveillance. Tumors 
treated with the Toll-like receptor (TLR)7 agonist imiquimod before excision showed induc-
tion of E-selectin on tumor vessels, recruitment of CLA  +   CD8  +   T cells, and histological 
evidence of tumor regression. SCCs treated in vitro with imiquimod also expressed vascular 
E-selectin. Approximately 50% of the T cells infi  ltrating untreated SCCs were FOXP3  +   
regulatory T (T reg) cells. Imiquimod-treated tumors contained a decreased percentage of T 
reg cells, and these cells produced less FOXP3, interleukin (IL)-10, and transforming growth 
factor (TGF)-    . Treatment of T reg cells in vitro with imiquimod inhibited their suppressive 
activity and reduced FOXP3, CD39, CD73, IL-10, and TGF-     by indirect mechanisms. In vivo 
and in vitro treatment with imiquimod also induced IL-6 production by effector T cells. In 
summary, we fi  nd that SCCs evade the immune response at least in part by down-regulat-
ing vascular E-selectin and recruiting T reg cells. TLR7 agonists neutralized both of these 
strategies, supporting their use in SCCs and other tumors with similar immune defects. 
© 2008 Clark et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the fi  rst six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons
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expression (not depicted). Few SCC T cells were Th2 biased 
as demonstrated by the lack of two independent markers for 
Th2 bias, ST2L and the     -IFN receptor      chain (  Fig. 1 A  ) 
(  14  –  16  ). Analysis of cytokine production by intracellular fl  ow 
cytometry confi  rmed that most T cells from SCCs were Th1 
biased (  Fig. 1 C  ). 
  T cells resident in human skin have a diverse T cell reper-
toire, consistent with their role in immunosurveillance against 
a variety of pathogens and tumors (  9  ). T cells in cervical can-
cers have a more biased repertoire, refl  ecting local expansion 
of tumor-specifi  c T cell clones (  17  ). We analyzed the TCR 
repertoire of T cells infi  ltrating SCCs by fl  ow cytometry for 
V     TCR subfamilies and found that these cells were diverse, 
without detectable V     bias (  Fig. 1 D  ). 
  Blood vessels of invasive SCCs in skin do not 
express E-selectin 
  E-selectin is a ligand for CLA that is expressed on postcapil-
lary venules in the skin. Vascular E-selectin is up-regulated 
with infl  ammation and supports the entry of CLA  +   T cells 
into the skin under both normal and infl  amed conditions (  11, 
12, 18  ). We examined tumor vessels for E-selectin expression 
by immunohistochemistry and found that blood vessels in 
areas surrounding the tumor (peritumoral areas) expressed 
E-selectin, but that blood vessels within the tumor parenchyma 
did not. (  Fig. 2, A  –  C  ).   Staining for CD31 was included to 
both healthy and immunocompromised individuals evade the 
immune response, at least in part, by down-regulation of vas-
cular E-selectin, exclusion of skin-homing memory T cells, and 
recruitment of regulatory T (T reg) cells. 
    RESULTS   
  SCCs are infi  ltrated by diverse noncutaneous central 
memory T cells 
  SCCs of the skin commonly have associated T cell infi  ltrates, 
but the clinical persistence of the cancer suggests that these 
T cells are unable to destroy the tumor (  7  ). We isolated T cells 
from human invasive SCCs and compared them with T cells 
from normal human skin, the population thought to provide 
immunosurveillance (  Fig. 1  ) (  8, 9  ).   Peripheral tissue eff  ector 
T cells express tissue-specifi  c homing receptors and preferen-
tially recirculate through the tissue in which they fi  rst en-
countered their antigens (  10, 11  ). Skin resident T cells express 
the skin addressins cutaneous lymphocyte antigen (CLA) and 
CCR4, which bind to E-selectin and CC chemokine ligand 
(CCL) 22 on skin endothelium (  9, 11, 12  ). T cells from SCCs 
did not express CLA and CCR4 (  Fig. 1 A  ) and instead ex-
pressed   l-  selectin and CCR7, markers of central memory T 
cells that are normally found only in the blood or lymph nodes 
(  13  ). Studies of cryosections confi  rmed that T cells from SCCs 
lack the skin addressin CLA (  Fig. 1 B  ). T cells from SCCs 
developing in transplant recipients also lacked CLA and CCR4 
  Figure 1.       T cells infi  ltrating SCCs are noncutaneous central memory T cells.   (A) T cells isolated from SCCs were memory (CD45RO  +  ) Th1-biased T 
cells that lacked expression of skin-homing addressins (CLA, CCR4) and instead expressed markers characteristic of central memory T cells (L-selectin/
CCR7), a cell type that is usually restricted to blood or lymph nodes. In contrast, T cells from normal human skin expressed high levels of the skin-homing 
addressins CLA and CCR4 and most lacked CCR7/L-selectin coexpression. Similar results were observed in three additional SCC samples. (B) Confi  rmation 
that T cells infi  ltrating SCCs lack CLA expression. Frozen sections of invasive SCCs were stained for CD3 (red) and CLA (green). Only a small number of T 
cells infi  ltrating SCCs were skin-homing T cells (CD3  + CLA +  , yellow). A higher magnifi  cation of the same fi  eld is also shown. (C) Intracellular cytokine analy-
sis of CD4  +   T cells from two SCC tumors demonstrated a Th1 bias with few Th2 or Th17 T cells present. Unstimulated cells produced no detectable cyto-
kines (not depicted). (D) Analysis of T cells from SCCs by fl  ow cytometry for TCR V     expression demonstrated signifi  cant TCR diversity. Analysis of two 
additional tumors showed comparable diversity. Bars, 100   μ  m.     JEM VOL. 205, September 29, 2008 
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ients on immunosuppressive medications also lacked vascular 
E-selectin within the tumors (not depicted). 
  Imiquimod-treated SCCs express vascular E-selectin 
and are infi  ltrated by CLA  +   skin-homing T cells 
  Imiquimod is a topical Toll-like receptor (TLR)7/8 ago-
nist that is eff  ective in the treatment of a wide range of skin 
identify blood vessels. This fi  nding was observed in all SCCs 
studied; we performed immunohistochemical stains on tu-
mors from four patients and conducted similar studies using 
three-color immunofl  uorescence analysis on tumors from fi  ve 
additional patients. Hoechst nuclear stain was used to con-
fi  rm the presence of invasive tumor in immunofl  uorescence 
studies. Two additional SCCs excised from transplant recip-
  Figure 2.       Blood vessels in areas of invasive SCCs do not express E-selectin, but imiquimod treatment induces vascular E-selectin expression 
and normalization of T cell homing.   (A) Serial sections of SCCs demonstrated the presence of CD31  +   blood vessels in areas of invasive SCCs, but 
these vessels lack E-selectin expression. (B) A second example is shown, in which tumor and peritumoral areas were present in a single stained section. 
(C) Immunofl  uorescence studies on a third sample stained for CD31 (green) and E-selectin (red), showing no E-selectin expression on tumor vessels. (D) SCCs 
treated with imiquimod before excision were heavily infi  ltrated with CLA  +   (skin-homing) cytotoxic T cells. (E) A subset of tumor vessels in imiquimod-
treated SCCs expressed E-selectin. (F) A second sample showing E-selectin expression on a subset of vessels embedded within a tumor nodule after im-
iquimod treatment. Large atypical keratinocytes forming a tumor nodule are demonstrated by Hoechst stain (blue). (G) In vitro treatment of SCC tumor 
tissue with imiquimod up-regulated E-selectin on a subset of tumor vessels. 2-mm bread loaf sections of untreated SCC tumor were incubated for 24 h in 
control medium, TNF-    , or imiquimod. Samples were then frozen, sectioned, and stained for CD31 and E-selectin. In all studies, Hoechst nuclear stain was 
used to identify areas of invasive tumor. Bars: (B, C, E, and F) 100   μ  m.     2224 IMMUNE EVASION IN SQUAMOUS CELL CARCINOMAS OF THE SKIN   | Clark et al. 
immunocompromised patients had greatly increased numbers 
of FOXP3  +   T reg cells when compared with the population 
found in normal skin (  Fig. 4 A  ). SCC FOXP3  +   T reg cells 
were CD4  +  , lacked expression of addressins found on skin 
resident T reg cells (CLA, CCR4, and CCR6) (  20  ), and in-
stead expressed markers of central memory T cells (  Fig. 4 B  , 
  l  -selectin/CCR7  +  ). FOXP3 is expressed at high and con-
stant levels by T reg cells, but expression of FOXP3 is also tran-
siently increased in activated non  –  T reg cells (  20, 21, 24  ). Our 
earlier work has shown that although activated T cells in-
crease expression of FOXP3, this transient increase was 
small and did not obscure the identifi  cation of true T reg cells, 
which expressed FOXP3 at levels a log higher than activa-
ted non  –  T reg cells (  20  ). CD127 negativity has recently been 
reported to discriminate between T reg cells and effector 
  malignancies, including basal cell carcinomas and SCCs (  19  ). 
We studied invasive SCCs treated with imiquimod from 
10 to 14 d before tumor excision (mean 12.7 d). All treated 
tumors exhibited areas of fi  brosis surrounding the tumors, 
consistent with stromal changes of tumor regression (not de-
picted). Imiquimod-treated SCCs contained   >  80% CD8  +   
cytotoxic T cells and, in contrast to untreated tumors, the 
majority of these T cells expressed CLA (  Fig. 2 D  ). The ma-
jority also lacked   l-  selectin and CCR7 coexpression, sug-
gesting a shift toward eff  ector memory cells, the type normally 
found within the skin (  9  ). T cells also expressed CCR6, but 
most lacked CCR4. 
  In contrast to untreated tumors, vessels of imiquimod-
treated SCCs expressed E-selectin on a subset of tumor 
vessels (  Fig. 2, E and F  ). Human endothelial cells have not 
previously been shown to respond to imiquimod. To study 
the ability of imiquimod to induce E-selectin expression 
ex vivo, we cultured portions of an untreated SCC tumor 
with imiquimod or TNF-     in vitro. Imiquimod and TNF-     
had similar eff  ects; both induced E-selectin expression on a 
subset of tumor vessels, likely representing postcapillary ven-
ules (  Fig. 2 G  ). 
  Imiquimod indirectly up-regulates E-selectin on human 
endothelial cells 
  To determine if endothelial cells were the direct targets of 
imiquimod, we measured the expression of TLR7 and TLR8 
in dermal microvascular endothelial cells by immunostaining 
and real-time PCR. Blood vessels in SCCs expressed TLR7 
and TLR8 by immunostaining (  Fig. 3 A  ).   However, TLR 
antibodies can be cross-reactive, so expression was con-
fi  rmed by real-time PCR analysis of purifi  ed cultures of dermal 
microvascular endothelial cells (  Fig. 3 B  ). Although purifi  ed 
endothelial cells expressed TLR7 and TLR8, they did not 
up-regulate E-selectin when treated in vitro with imiquimod 
(  Fig. 3 C  ). In contrast, inclusion of activated APCs in the co-
cultures or overnight treatment with TNF-     resulted in a 
robust induction of E-selectin. 
  To determine if SCC tumor cells could suppress endo-
thelial expression of E-selectin, we co-cultured endothelial 
cells with the SCC cell line SCC13 in the presence or absence 
of imiquimod and TNF-     (  Fig. 3 D  ). We found no eff  ect on 
the baseline or induced levels of endothelial E-selectin, sug-
gesting that SCC tumor cells themselves do not directly sup-
press vascular E-selectin expression. 
  SCCs are infi  ltrated by FOXP3  +   T reg cells 
  We further characterized the central memory T cells infi  l-
trating SCCs and found they contained a large population of 
CD25  hi  CD69  lo   T cells, a phenotype similar to that of natural 
T reg cells (  Fig. 4 A  ) (  20  ).   Natural T reg cells, which develop 
as a separate lineage within the thymus, can be distinguished 
from other T cells by their constant and high expression of the 
transcription factor FOXP3 (  21  –  23  ). We and others have found 
excellent correlation of high FOXP3 expression with suppre-
ssive ability (  20  ). T cells isolated from SCCs of both normal and 
  Figure 3.       Imiquimod up-regulates E-selectin on endothelial cells 
by an indirect mechanism.   (A)  Immunofl  uorescence studies on frozen 
sections of SCC tumor stained for the vascular marker CD31 (green) 
and TLR7 or TLR8 (red). (B) Confi  rmation of TLR7 and TLR8 expression 
by real-time quantitative PCR. Cultured dermal microvascular endo-
thelial cells were analyzed for TLR7 and TLR8 expression and com-
pared with T cell  –  depleted peripheral blood mononuclear cells (APCs). 
(C) Imiquimod does not directly induce E-selectin on endothelial cells. 
Purifi  ed human endothelial cells were cultured with imiquimod or acti-
vated APC for 3 d or TNF-     for 12 h, and then harvested and assayed 
by fl  ow cytometry for the expression of CD31 and E-selectin. Experi-
ments using two additional endothelial cell donors produced similar 
results. (D) SCC tumor cells do not suppress baseline or induced 
E-selectin expression on endothelial cells. SCC13 tumor cells were co-
cultured with endothelial cells in control medium (SCC), with imiqui-
mod (SCC+imiquimod) or with TNF-     (SCC+TNF-   ). No changes in 
basal or induced levels of endothelial E-selectin were observed. Experi-
ments using two additional endothelial donors produced similar re-
sults. Bar, 100    μ  m.     JEM VOL. 205, September 29, 2008 
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receptors (  Fig. 1  ). We therefore confi  rmed our fi  ndings 
using primary SCC tumor tissue. We used three-color 
immunofl  uorescence staining of frozen sections of SCC tu-
mors to enumerate non  –  T reg (FOXP3       CD3  +  ) and T reg 
(FOXP3  +  CD3  +  ) cells in areas of invasive SCCs. Nearly 50% 
of the T cells infi  ltrating SCCs from both normal and immuno-
suppressed patients were FOXP3  +   T reg cells (  Figs. 4 E and 
5 C  ).   Approximately 50  –  60% of the total T cells in SCCs 
were CD4  +   (  Fig. 1 A  ), suggesting that the vast majority 
of CD4  +   T cells in SCCs are actually FOXP3  +   T reg cells. 
cell populations in humans (  25  –  27  ); we found that SCC 
FOXP3  +   T cells lacked expression of CD127, suggesting 
that they do not represent recently activated non  –  T reg cells 
(Fig. S1, available at http://www.jem.org/cgi/content/full/
jem.20071190/DC1). 
  Our method of T cell isolation from skin depends upon 
the ability of T cells to migrate out of the skin in response to 
chemokines produced by dermal fi  broblasts (  28  ). T cells with 
central memory markers may not migrate effi   ciently to skin 
cell chemokines because they express diff  erent chemokine 
  Figure 4.       SCCs are heavily infi  ltrated by FOXP3  +   T reg cells recruited from blood.   (A) T cells isolated from SCCs developing in normal individuals 
and transplant recipients contained many CD25  hi FOXP3 +   T reg cells. (B) T reg cells isolated from SCCs were CD4  +   central memory T cells (L-selectin/CCR7  + ) 
and were distinct from cutaneous T reg cells found in normal skin as shown by their lack of expression of key skin-homing addressins (CLA, CCR4). The 
last two graphs are gated to show only CD3  + FOXP3 +   T cells. (C) Direct study of FOXP3  +   T reg cells in areas of invasive SCCs using immunofl  uorescence 
staining of frozen sections. SCCs were stained for CD3 (red) and FOXP3 (green). Two FOXP3  +   T reg cells are shown at the top of the left image, and a 
FOXP3        nonregulatory T cell is shown on the bottom. A larger fi  eld is shown in the right image. (D) A lower magnifi  cation image of another SCC, demon-
strating that large numbers of FOXP3  +   T reg cells (red cells with green nuclei) surround nodules of invasive tumor, which appear as pools of green sec-
ondary to nonspecifi  c staining of tumor keratin. (E) Enumeration of T reg cells in frozen sections of SCCs. The number of T reg cells and nonregulatory T 
cells were counted in 10 high power (40X) fi  elds in SCCs from normal patients (Immunocompetent) and transplant recipients (Transplant rcp) and the 
results were compared with that of normal skin. Shown are the mean and SD of counts from 10 fi  elds. (F) FOXP3  +   T reg cells are not locally expanded 
within SCCs. SCC sections were costained for FOXP3 and Ki-67, a marker of cell proliferation. Proliferative and nonproliferative FOXP3  +   T reg cells were 
counted in 5 hpf for each donor; the mean and SD for each tumor are shown. SCC9 and 10 are from immunocompetent individuals; SCC11 is from a 
transplant recipient. Bars: (C, left) 10   μ  m; (C, right, and D) 100   μ  m.     2226 IMMUNE EVASION IN SQUAMOUS CELL CARCINOMAS OF THE SKIN   | Clark et al. 
these cells was reduced to roughly 10%, similar to that found 
in normal human skin (  Fig. 5, B and C  ). 
  Imiquimod inhibits T reg cell function 
  TLR8 agonists can block the ability of T reg cells to suppress 
T cell responses, suggesting that imiquimod may have an ef-
fect on tumor-associated T reg cells (  29  ). We isolated T reg 
cells from normal human skin and studied the eff  ect of imiqui-
mod on these cells. In vitro treatment of purifi  ed skin T cells 
with imiquimod for 1 wk had no direct eff  ect on the viability 
of FOXP3  +   T reg cells, suggesting that T reg cells are not 
depleted by imiquimod (  Fig. 5 D  ). Our previous studies dem-
onstrate that skin-resident natural T reg cells proliferate in re-
sponse to culture with dermal fi  broblasts and IL-15 (  20  ). We 
found that imiquimod only slightly reduced proliferation 
of FOXP3  +   T reg cells under these conditions (  Fig. 5 E  ). 
To study T reg cell function, we cultured skin explants with 
To determine if T reg cells are recruited from the blood or 
locally expanded within the tumor, we stained tumors for ex-
pression of Ki-67, an antigen expressed by dividing cells. We 
observed very few proliferating T reg cells in SCCs, suggesting 
that recruitment of these cells from the blood is the predomi-
nant mechanism for their accumulation within SCCs (  Fig. 4 F  ). 
  Imiquimod treatment is associated with decreased 
percentages of FOXP3  +   T reg cells 
  T cells isolated from SCC tumors treated with imiquimod 
contained decreased percentages of FOXP3  +   T reg cells (  Fig. 
5 A  ). We counted the absolute number of T reg cells in the 
cryosections of imiquimod-treated tumors and found that this 
drop in the percentage of T reg cells resulted from a marked 
infl  ux of non  –  T reg cells into the tumor, most of which were 
cytotoxic CD8  +   T cells (  Figs. 5 B and 2 D  ). FOXP3  +   T reg 
cells were still present in treated tumors, but the percentage of 
  Figure 5.       Imiquimod-treated SCCs contain decreased percentages of FOXP3  +   T reg cells and imiquimod treatment in vitro blocks the 
ability of T reg cells to suppress.   (A) T cells isolated from imiquimod-treated SCCs contain few detectable FOXP3  +   T reg cells. (B) Direct enumera-
tion of FOXP3  +   T reg cells in sections of imiquimod-treated SCCs (tx). Counts from untreated SCCs (untx) are shown for comparison. Mean and SD are 
shown. (C) Percentage of FOXP3 T reg cells infi  ltrating normal human skin (nml), untreated SCC tumors (untx, triangles; SCCs from healthy individ-
uals, circles; SCCs from transplant recipients) and imiquimod-treated SCCs (tx). Bars indicate the SD of the percentage of T reg cells from 10 hpf. 
(D) Imiquimod does not affect the viability of nonregulatory T cells (FOXP3       ) and FOXP3  +   T reg cells (FOXP3  +  ) isolated from human skin. Viability was 
assessed after 1 wk of incubation in either control medium or imiquimod. (E) Imiquimod only slightly inhibits the proliferation of skin-derived T reg 
cells. T cells from human skin were labeled with CFSE and cultured with dermal fi  broblasts and IL-15 for 1 wk in the presence or absence of imiqui-
mod. Cells were then stained for FOXP3 expression. FOXP3  +   T reg cells that have proliferated are shown in the top left quadrant of each histogram. 
(F) Imiquimod treatment paralyzes regulatory T cell function. T cells isolated from human skin were cultured for three days in control medium (untx, 
gray bars) or imiquimod (tx, black bars), and then separated into T reg cells, enriched CD25  hi   T cells (CD25  hi  ), and responder CD25  lo   T cells (CD25  lo ). 
Cells were stimulated with soluble anti-CD3 and   –  CD28 and proliferation was assayed by incorporation of [  3  H]thymidine. Untreated CD25  hi   sup-
pressed CD25  lo   T cell proliferation, but pretreatment of CD25  hi   cells with imiquimod blocked suppression. Suppression of imiquimod-treated CD25  lo  
was restored by adding untreated CD25  hi   T cells, demonstrating that the suppressive defect was is the CD25  hi   subset. (G) At least three days of im-
iquimod pretreatment is required for loss of suppressive function. Skin T cells were cultured in control medium (squares) or imiquimod (circles) for 
the indicated length of time, and then cells were sorted and analyzed for suppressive ability. Bars indicate the SD of experiments from two different 
skin donors.     JEM VOL. 205, September 29, 2008 
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reg cells (not depicted). These fi  ndings suggested that imiqui-
mod may aff  ect both T reg and non  –  T reg cells. 
  Imiquimod indirectly up-regulates IL-6 production 
by effector T cells 
  In our suppression assays, imiquimod was added to skin ex-
plant cultures during the fi  nal period before T cell collection. 
We could not determine from these experiments if the eff  ects 
of imiquimod on T cells were direct or were mediated by 
factors produced by other cells within the skin. 
  Imiquimod induces the production of IL-6 from human 
monocytes, plasmacytoid DCs (PDCs), and keratinocytes, 
and the production of IL-6 by T cells or nearby DCs has 
been shown in mice to render T cells resistant to suppression 
by T reg cells (  30  –  34  ). T cell expression of IL-6 in response 
to imiquimod has not been previously reported. We found 
that the addition of imiquimod to skin explant cultures for 
1 wk induced IL-6 expression in 22% (SD of 0.2) of skin 
T cells compared with a baseline expression of 5.5% (SD of 
2.5;   Fig. 6, A and B  ).   We then examined T cells isolated from 
SCCs treated in vivo with imiquimod and found that 53% 
(SD of 0.64) of T cells from treated tumors produced IL-6, 
either imiquimod or control medium for 3  –  5 d. We then col-
lected T cells from explant cultures, isolated enriched popula-
tions of FOXP3  +   T reg cells by high speed fl  ow cytometry 
sorting for CD3  +  CD4  +  CD25  hi  CD69  lo   T cells, and tested the 
ability of these cells to suppress the proliferation of T cells iso-
lated from the same skin sample, as described previously (  20  ). 
When suppression assays, which lasted 6 d, were performed in 
the absence of imiquimod, we found that CD25  hi   T reg cells 
pretreated for 3 d with imiquimod failed to suppress T cell 
proliferation, whereas untreated CD25  hi   T reg cells from the 
same sample of skin did suppress T cell responses (  Fig. 5 F  ). 
The reciprocal experiment showed that pretreatment of both 
CD25  lo   responder cells and CD25  hi   T reg cells with imiqui-
mod showed no suppression, but the addition of untreated 
CD25  hi   T cells restored suppression. This eff  ect depended on 
the pretreatment of T reg cells with imiquimod; 5 d of pre-
treatment with imiquimod produced similar results, but 2 d 
of treatment induced only a partial loss of suppressive ability, 
suggesting that inactivation of T reg cells required at least 3 d 
of imiquimod treatment (  Fig. 5 G  ). When imiquimod was 
additionally added to suppression assays, we found that eff  ec-
tor T cells were less susceptible to suppression by untreated T 
  Figure 6.       Imiquimod induces IL-6 production by effector T cells and reduces FOXP3 and production of IL-10 and TGF-     by T reg cells.  
(A) Imiquimod treatment induces IL-6 production by T cells in vitro and in vivo. Imiquimod or control medium was added to explant cultures of nor-
mal human skin for 1 wk. T cells were then isolated from these cultures and examined for IL-6 production. Imiquimod treatment of purifi  ed skin T 
cells alone had no effect. T cells were isolated from SCCs that were either untreated (SCC16) or treated in vivo with topical imiquimod (SCC8, 17, 18) 
and analyzed for IL-6 production. Histograms of SCC T cells are gated to show only CD3  +   T cells. (B) IL-6 production from multiple donors after in 
vitro (skin T cells) or in vivo (SCC; 8, 17, 18) treatment with imiquimod. (C) FOXP3 expression as assayed by mean fl  uorescence intensity (MFI) under 
identical staining conditions in T cells from normal skin explant cultures (NS) treated for 1 wk with control medium (triangle) or imiquimod (circle, 
mean and SD of three determinations are shown) or from untreated SCCs (16; triangle) or SCCs treated in vivo with imiquimod (circles; 8, 16, 18). 
(D) IL-10 and TGF-     production as determined by intracellular cytokine analysis of FOXP3  +   T reg cells isolated from untreated (SCC16) or imiquimod 
treated SCCs (SCC17). (E) IL-10 and TGF-     production by FOXP3  +   T reg cells isolated from normal skin explant cultures (NS) treated for 1 wk with 
control medium (white bars) or imiquimod (black bars) and by FOXP3  +   T reg cells isolated from untreated SCCs (16) or SCCs treated in vivo with 
imiquimod (8, 17, 18).     2228 IMMUNE EVASION IN SQUAMOUS CELL CARCINOMAS OF THE SKIN   | Clark et al. 
reduced the expression of both CD39 and CD73 on T reg cells 
(Fig. S2, available at http://www.jem.org/cgi/content/full/jem
.20071190/DC1). Treatment of purifi  ed skin T cells with im-
iquimod did not aff  ect T reg cell surface marker expression or 
cytokine production, arguing for an indirect mechanism of ef-
fect. In summary, we fi  nd that imiquimod decreases T reg cell 
FOXP3, CD39, and cytokine production and that this eff  ect is 
dependent on the presence of other cells resident in skin. 
compared with 10% from an untreated SCC (  Fig. 6, A and B  ). 
In contrast, culture of purifi  ed skin T cells with imiquimod 
did not induce IL-6 production (not depicted), suggesting 
that IL-6 induction occurs by an indirect mechanism. 
  Imiquimod indirectly decreases expression of FOXP3, IL-10, 
TGF-    , CD39, and CD73 
  Our suppression assays demonstrate that imiquimod inhibits the 
ability of T reg cells to suppress. To study this further, we exam-
ined the eff  ect of imiquimod on T cells isolated from human skin. 
When imiquimod was added to explant cultures for 1 wk before 
T cell isolation, expression of the FOXP3 protein by T reg cells 
was signifi  cantly decreased (  Fig. 6 C  ). FOXP3 protein expression 
by T reg cells correlates with their ability to suppress T cell re-
sponses (  21  ). We then examined FOXP3 expression in T reg cells 
isolated from SCCs and found that although levels of FOXP3 in 
imiquimod-treated tumors tended to be lower than in untreated 
SCCs, this diff  erence was not signifi  cant (  Fig. 6 C  ). 
  T reg cells can suppress T cell responses by the production of 
cytokines such as IL-10 and TFG-    , and by cell-contact mech-
anisms shown recently to involve, in part, the action of CD39 
and CD73 on T reg cells (  35  ). Imiquimod added to skin explant 
cultures decreased the production of both IL-10 and TFG-     by 
FOXP3  +   T reg cells (  Fig. 6 E  ). Moreover, in addition to being 
present at fi  vefold lower numbers, T reg cells isolated from SCCs 
treated in vivo with imiquimod produced less IL-10 and TFG-     
(  Fig. 6, D and E  ). Lastly, we found that CD39 and CD73 were 
preferentially expressed by FOXP3  +   T reg cells versus FOXP3        
eff  ector T cells, and that treatment in vitro with imiquimod 
  Figure 7.       SCCs contain immature and iNOS  +   DCs.   Cryosections of untreated and imiquimod-treated SCCs were immunostained for the DC marker 
CD11c and markers of DC maturation CD83 (A) and DC-LAMP (B). Numerous immature DCs were present in untreated SCCs, whereas treated SCCs con-
tained signifi  cant numbers of mature DC. Untreated SCCs also contained a population of cells that expressed high levels of iNOS (C, indicated by arrow), 
but these cells were not detected in imiquimod-treated SCCs. There was also some staining of tumor cells (T) in both untreated and treated tumors. 
A concentration-matched isotype control for iNOS staining is shown in the fi  rst image. Bars, 100   μ  m.     
  Figure 8.       Imiquimod treated tumors contain expanded populations 
of TCR-biased cytotoxic T cells.   T cells were isolated from untreated 
and imiquimod-treated SCCs and analyzed for V     expression by fl  ow 
cytometry. Data are presented as the absolute number of CD8  +   T cells of 
each V     family in 100 hpf. Imiquimod-treated tumors contained larger 
numbers of cytotoxic T cells, and these T cells had clearly biased V     reper-
toires, consistent with local expansion of tumor-specifi  c T cells.     JEM VOL. 205, September 29, 2008 
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  Eff  ector memory T cells preferentially migrate through 
the peripheral tissue in which they fi  rst encountered antigen 
(  10, 11  ). This tissue-specifi  c migration ensures that tissues are 
populated by T cells specifi  c for pathogens likely to be en-
countered again in that tissue. Such T cells can migrate pref-
erentially because they express addressins that bind to specifi  c 
counterreceptors on the endothelium of a particular tissue. 
For example, CLA on skin-homing T cells binds to E-selec-
tin expressed on cutaneous postcapillary venules, supporting 
the entry of T cells into the skin under both normal and in-
fl  amed conditions (  11, 12, 18  ). SCC-specifi  c T cells should 
express CLA because they fi  rst encounter antigen within the 
skin-draining lymph nodes. We have found that SCCs do 
not express E-selectin on tumor vessels and are not infi  ltrated 
by CLA  +   skin-homing T cells. The tumor therefore excludes 
the population of skin-homing memory T cells expected to 
contain tumor-specifi  c T cells. We observed a lack of vascular 
E-selectin and exclusion of CLA  +   T cells from SCCs arising 
in both normal and immunosuppressed individuals, suggest-
ing that aberrant T cell homing occurs in tumors from both 
clinical groups. 
  Impaired T cell homing also occurs in other types of hu-
man cancer. Reduced expression of adhesion molecules on 
blood vessels has been described in human breast, gastric, and 
lung cancer (  41, 42  ). Melanoma metastases express low levels 
of the addressins E-selectin, P-selectin, and ICAM-1, and this 
is associated with low numbers of T cells within the meta-
static tumor nodules (  43  ). Because of its readily accessible lo-
cation, cutaneous SCC is a model cancer in which to study 
the defective T cell homing that may underlie poor immune 
responses to several human cancers. Additional studies of the 
nature of endothelial cells within SCCs will be critical to un-
derstanding how these tumors regulate the expression of vas-
cular addressins. 
  T reg cells can suppress the activation, cytokine produc-
tion, and proliferation of other T cells, and they are crucial to 
the development and maintenance of self-tolerance (  21, 44, 
45  ). We have found that up to 50% of the T cells infi  ltrating 
cutaneous SCCs from both normal and immunosuppressed 
individuals are FOXP3  +   T reg cells. These cells form a dense 
infi  ltrate surrounding tumor nests and are well positioned to 
impair the responses of eff  ector T cells that gain access to the 
tumor. T reg cells from SCCs lack CLA and CCR4 and are 
therefore distinct from the T reg cells that populate normal 
skin (  20  ). Instead, T reg cells from SCCs coexpress   l-  selectin 
and CCR7. This phenotype is similar to that of central mem-
ory T cells, a type of cell found normally only in the blood or 
lymph nodes. We observed no local proliferation of T reg cells 
in tumors (  Fig. 4 F  ), and thus recruitment from the blood 
may be the primary mechanism for enrichment of these 
cells in tumors. T reg cells are recruited to ovarian carcinoma 
by the interaction of tumor CCL22 with CCR4 on T reg 
cells, and recruitment of T reg cells to Hodgkin lymphomas 
also involves CCR4 (  46  ). However, CCR4 is highly expressed 
by T cells that provide immunosurveillance of the skin (  9  ), and 
recruitment of this subset would likely be detrimental to tumor 
  SCCs are infi  ltrated by immature and inducible nitric oxide 
synthase (iNOS)  +   DCs 
  We have found that two important eff  ects of imiquimod, the 
induction of vascular E-selectin and immunomodulation of 
T reg and eff  ector T cells, appear to occur via indirect mech-
anisms. Human dermis contains macrophages and dermal 
DCs, and SCCs also contain PDCs (  36, 37  ); these cell types 
have been reported to respond directly to imiquimod. We 
analyzed SCCs by immunostaining and found that these tu-
mors contain large numbers of CD11c  +   DCs (  Fig. 7, A and B  , 
DC).   However, most DCs were immature, as demonstrated 
by their lack of DC-LAMP and CD83 expression. In con-
trast, imiquimod-treated SCCs contained mature DCs ex-
pressing both CD83 and DC-LAMP, consistent with reports 
that imiquimod induces maturation of DCs (  31, 38  ). Addi-
tionally, a population of cells expressing high levels of iNOS 
was present in untreated but not imiquimod-treated SCCs 
(  Fig. 7 C  ). These cells co-stained weakly for CD11c, but 
were negative for CD34 (not depicted), suggesting that they 
represent DCs as opposed to myeloid-derived suppressor 
cells (  39, 40  ). 
  Imiquimod-treated tumors contain expanded clonal 
populations of cytotoxic T cells 
  Our fi  ndings suggest that imiquimod treatment allows the 
entry of tumor-specifi  c T cells into SCCs and may also block 
the ability of T reg cells to suppress the activity and prolifera-
tion of these cells once they enter the tumor. Expansion of 
tumor-specifi  c T cells would be expected to produce a skew-
ing of the T cell repertoire in imiquimod-treated tumors. 
To evaluate this, we analyzed the TCR repertoire of CD8  +   
T cells isolated from untreated and imiquimod-treated tu-
mors using flow cytometry for TCR V     families (  Fig. 8  ).   
Untreated tumors were infi  ltrated by small numbers of di-
verse CD8 T cells, but imiquimod-treated tumors contained 
larger numbers of CD8  +   T cells with a markedly skewed V     
repertoire. This skewed repertoire, together with the histo-
logical changes of tumor regression seen in treated tumors, 
suggests successful proliferation and infi  ltration of tumor-spe-
cifi  c CD8  +   T cells in treated but not in untreated tumors. 
    DISCUSSION   
  Cutaneous immunosurveillance is an invisible process when 
it is functioning properly. Normal human skin contains 1 mil-
lion memory T cells/cm  2  , and there are nearly twice as many 
T cells resident in normal skin than are present in the entire 
circulation (  9  ). This suggests that immune surveillance of the 
skin is a high priority for the immune system. The suscepti-
bility of individuals on T cell  –  immunosuppressant medications 
to SCCs suggests that T cells may play a role in controlling 
these tumors. We were intrigued by the fact that SCCs are 
heavily infi  ltrated by T cells that nonetheless fail to control 
tumor growth. We fi  nd that SCCs from both healthy and 
immunocompromised individuals exclude skin-homing mem-
ory T cells, and instead recruit a population of T reg cells 
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that distinguished progressively growing tumors from those 
that spontaneously regressed (  61  ). Thus, the dilution of tu-
mor T reg cells by recruitment or local expansion of CD8  +   T 
cells may tip the balance toward immunological destruction. 
  We hypothesized that imiquimod may inhibit tumor-as-
sociated T reg cells, given that TLR8 ligation was recently 
shown to block the suppressive ability of T reg cells (  29  ). In-
deed, we found that treatment of T reg cells with imiquimod 
in vitro blocked their ability to suppress T cell proliferation 
without reducing viability. Imiquimod treatment decreased 
the expression of FOXP3 and production of the cytokines 
IL-10 and TGF-     in T reg cells isolated from human skin. 
CD39 and CD73 have been recently implicated in contact-
dependent suppression by T reg cells in mice; we found that 
both CD39 and CD73 were preferentially expressed by T reg 
cells and that expression was down-regulated after treatment 
with imiquimod (  35  ). These eff  ects were observed if imiqui-
mod was added to the skin explant cultures before T cell iso-
lation, but direct treatment of purifi  ed skin T cells had no 
eff  ect, suggesting an indirect mechanism mediated by   another 
cell type present in skin. Candidate responsive cells in skin 
include PDCs, macrophages, and keratinocytes, each of which 
has been shown to respond directly to imiquimod (  30  –  32  ). 
T reg cells isolated from SCCs treated in vivo with imiquimod 
also had decreased IL-10 and TGF-     production, confi  rming 
that the eff  ects we see in vitro are also present in vivo. 
  In addition to the eff  ect on T reg cells, imiquimod in-
duced the production of IL-6 by eff  ector T cells, albeit by an 
indirect mechanism. To our knowledge, imiquimod-stimu-
lated IL-6 production by T cells has not been reported previ-
ously. IL-6 production by murine T cells renders them 
resistant to suppression by T reg cells, and early reports suggest 
a similar eff  ect occurs in human psoriatic T cells (  34, 62, 63  ). 
Thus, TLR agonists such as imiquimod both decrease the 
suppressive activity of T reg cells and increase the resistance 
of eff  ector cells to suppression. Again, this eff  ect was indirect 
and required the presence of other cells in skin. Over 50% 
of effector T cells isolated from imiquimod-treated SCCs 
produced IL-6, compared with 10% in an untreated tumor, 
confi  rming the in vivo relevance of this fi  nding. Studies to 
identify the imiquimod-responsive cells in skin and the sig-
nals that mediated endothelial and T cell responses to imiqui-
mod are ongoing in our laboratory. 
  The indirect nature of imiquimod  ’  s eff  ects on endothelial 
and T cells highlights the critical role of innate immune cells 
such as DCs in tumor responses. We found large numbers 
of immature DCs in untreated SCCs, whereas mature DCs 
were evident only after imiquimod treatment. Immature DCs 
within tumors can prevent proper antigen presentation and 
can induce the formation of T reg cells (  64  ). We also ob-
served a population of iNOS-expressing DCs in untreated, 
but not treated, SCCs. Nitric oxide (NO) impairs the ability 
of human endothelial cells to express E-selectin in vitro (  65, 
66  ). Exogenously produced NO down-regulates the expression 
of MAdCAM-1 on gut vessels, decreases lymphocyte rolling, 
and has been proposed as a possible therapy for infl  ammatory 
survival. In fact, we see no expression of CCR4 on the T reg 
cells infi  ltrating SCCs, suggesting another addressin must be 
responsible for recruiting these and other central memory 
T cells into tumors. Preliminary studies in our laboratory 
have shown that SCC vessels do not express peripheral node 
addressin, a group of   l-  selectin ligands that recruit memory 
and naive   l-  selectin  –  expressing T cells into lymph nodes, nor do 
they express the CCR7 ligands CCL19 and CCL21 (unpub-
lished data) (  47  ). This is consistent with the lack of CD45RA  +   
naive T cells in tumors. Ongoing studies in our laboratory 
are focused on identifying the vascular ligands expressed by 
SCC tumor vessels that support the recruitment of central 
memory T cells. 
  Imiquimod is a topical immune response modifi  er that is 
eff  ective in the treatment of basal cell carcinomas, SCCs, and 
SCC precursor lesions actinic keratoses (  19  ). Imiquimod in-
duces tumor regression via both immunological and nonim-
munological mechanisms by activating TLR7 and TLR8 and 
binding to adenosine receptors (  48  –  51  ). Imiquimod stimu-
lates blood mononuclear cells to produce a variety of infl  am-
matory cytokines, including IFN-    , TNF-    , IL-1, IL-12, 
IL-6, IL-8, and IL-10 (  32, 52  –  56  ). Clinical response to topi-
cal imiquimod has been associated with the migration of 
PDCs into the skin and subsequent cytokine production (  57, 
58  ). It has been suggested that SCCs may be infi  ltrated by 
Th2-biased T cells, and that clearance of these tumors after 
imiquimod therapy might be a result of a shift from Th2- to 
Th1-biased immunity (  59  ). However, we found very few 
Th2-biased T cells in SCCs (  Fig. 1 A  ). Thus, lack of tumor 
destruction is not likely a result of Th-2 bias among tumor-
infi  ltrating T cells. 
  Our results show that treatment of SCC with imiquimod 
is associated with induction of E-selectin on tumor vessels, 
infi  ltration by CLA  +   skin-homing CD8  +   cytotoxic T cells, 
and histological evidence of tumor regression. In vitro treat-
ment of SCCs with imiquimod induced E-selectin on tumor 
vessels, suggesting that this medication may act to restore nor-
mal T cell homing, allowing CLA  +   skin-homing T cells access 
to the tumor, where they can initiate tumor destruction. 
We have found that SCC blood vessels and dermal microvas-
cular endothelial cells express TLR7 and TLR8, but do not 
respond directly to imiquimod. Vascular responses to im-
iquimod therefore require the presence of APCs or other 
imiquimod-responsive cell types. To respond directly to 
TLR7/8 agonists, a cell must take up and deliver agonists to 
the endosomal compartment where TLR7/8 are located, and 
endosomes must subsequently undergo acidifi  cation and mat-
uration (  60  ). Thus, human endothelial cells may not respond di-
rectly to TLR7/8 agonists because they are nonphagocytic or 
lack endosomal maturation. 
  In addition to its eff  ect on E-selectin expression, imiqui-
mod treatment of SCC results in a fi  vefold reduction in the 
percentage of tumor-infi  ltrating FOXP3  +   T reg cells. Treated 
tumors contain vastly increased numbers of CD8  +   T cells, in 
essence diluting out tumor T reg cells. In a mouse model of 
sarcoma, it was the relative percentage of FOXP3  +   T reg cells JEM VOL. 205, September 29, 2008 
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secondary antibody was added (1:100 dilution) for 30 min, followed by 
three rinses. Sections were stained with 0.5   μ  g/ml Hoechst stain for 2 min, 
rinsed briefl  y in PBS/1% BSA, and then mounted using Prolong anti-fade 
mounting medium (Invitrogen) and examined immediately by immuno-
fl  uorescence microscopy. Antibodies were obtained from the following: 
BD Biosciences (CLA, CD3, CD8, CD31, E-selectin, and Ki-67), Imgenex 
(TLR8 clone 44C143, TLR7, CD83, and DC-LAMP), and R  &  D Systems 
(CD11c). In all studies, Hoechst nuclear stain was used to confi  rm the pres-
ence of invasive tumor. Sections were photographed using a microscope 
(Eclipse 6600; Nikon) equipped with a 40  ×  /0.75 objective lens (Plan Fluor; 
Nikon). Images were captured with a camera (SPOT RT model 2.3.1; 
Diagnostic Instruments) and were acquired with SPOT 4.0.9 software 
(Diagnostic Instruments). 
  Cytokine analysis.     T cells from SCC tumors were stimulated with either 
control medium or 50 ng/ml PMA and 750 ng/ml ionomycin for 6 h; 
10   μ  g/ml Brefeldin A (Calbiochem) was added after 1 h. Cells were stained 
for surface markers, fi  xed, permeabilized, stained with anticytokine anti-
bodies, and examined by fl  ow cytometry. 
  TCR diversity analysis of tumor-infi  ltrating T cells.     T cells were iso-
lated from SCC tumors via 1 wk explant cultures and examined by fl  ow cytom-
etry for V     expression, CD3, CD4, and CD8. V     staining was performed 
using the IOtest Beta Mark TCR V      Repertoire kit (Beckman Coulter) as 
per manufacturer  ’  s instructions. For   Fig. 6  , the number of CD8 T cells in 
100 high power fi  elds (hpf) was calculated for each V     family by the follow-
ing formula: (percentage of V     expression)   ×   (mean number of T cells in 
1 hpf from   Fig. 4 E and Fig. 5 B  )   ×   (100). 
  Immunohistochemical studies.     For detection of CD31 and E-selectin 
on SCC blood vessels, 5-  μ  m sections were cut and stored as described in 
Immunofl   uorescence studies. Sections were fi  xed in     20  °  C acetone for 
5 min, air dried, and incubated with 4   μ  g/ml primary antibody or 4   μ  g/ml 
of mouse IgG as a negative control for 1 h at room temperature. Sections 
were washed in PBS three times for 5 min, and then incubated with a 1:200 
dilution of secondary antibody at room temperature for 30 min. Sections 
were washed three times in PBS, incubated with ABC-peroxidase at room 
temperature for 30 min, and then washed three times in PBS. The substrate 
reaction was performed for 30 s (CD31) or 2.5 min (E-selectin). Sections 
were then counterstained with hematoxylin (Gill  ’  s No. 1; Thermo Fisher 
Scientifi  c). Primary anti-CD31 was obtained from Dako, anti  –  E-selectin 
was purchased from R  &  D Systems, and secondary antibody was biotinyl-
ated horse anti  –  mouse IgG (Vector Laboratories). The Vectastain Elite stan-
dard ABC-peroxidase kit and NovaRED substrate were obtained from 
Vector Laboratories. 
  Real-time quantitative PCR for endothelial cell expression of TLR7 
and TLR8.     Human adult dermal microvascular endothelial cells were pur-
chased from Cambrex Corporation and cultured in endothelial basal me-
dia (Clonetics Corp.) supplemented with 25   μ  g/ml dibutyryl cyclic AMP 
(Sigma-Aldrich), 1   μ  g/ml hydrocortisone acetate (Sigma-Aldrich), 20% heat-
inactivated FCS, 100 U/ml penicillin, and 100   μ  g/ml streptomycin. RNA 
was isolated from second passage cultures. For comparison, identical studies 
were performed on T cell  –  depleted PBMCs, isolated from peripheral blood 
by Ficoll density centrifugation followed by T cell depletion using the pan  –
  T cells isolation kit (Miltenyi Biotech) and AutoMACS instrument (Miltenyi 
Biotech). For RNA extraction and cDNA synthesis, cells were placed in 
RNALater RNA-stabilizing reagent (QIAGEN) and frozen at     80  °  C for 
later use. Frozen cells were then lysed and homogenized, and total RNA 
was extracted using QIAGEN RNeasy mini kits as specifi  ed by the manu-
facturer. Avian RT fi  rst-strand kits (Sigma-Aldrich) were used to synthesize 
cDNA from total RNA. The concentration of total RNA was determined 
at the optical density at 260 nm (OD  260  ), and discrepancies in the amount 
of total RNA extracted were corrected by loading the same amount and 
concentration of RNA for cDNA synthesis. The purity of cDNA was 
bowel disease (  67  ). We are currently investigating the possi-
bility that NO production suppresses E-selectin expression 
on tumor vessels. 
  We have evidence for three novel mechanisms of action 
for imiquimod that may initiate and sustain the immunological 
destruction of SCC. First, imiquimod up-regulates E-selectin 
on tumor vessels. This E-selectin expression is associated with 
an infl  ux of CLA  +   cytotoxic T cells into the tumor, there    by 
delivering potentially tumor-reactive T cells to the cancer 
while at the same time diluting out tumor T reg cells. Second, 
imiquimod inhibits the suppressive activity of T reg cells, 
decreasing the levels of FOXP3 protein and surface molecules 
associated with contact inhibition, as well as reducing the 
production of immunosuppressive cytokines. Lastly, imiquimod 
induces the production of IL-6 by eff  ector T cells that may 
render them resistant to suppression by T reg cells. 
  Impaired T cell homing and recruitment of regulatory T 
cells are features of many human cancers. We fi  nd that the 
TLR7 agonist imiquimod neutralizes both of these defenses, 
supporting the use of this medication in SCCs and in other tu-
mors that use similar strategies to evade the immune response. 
  MATERIALS AND METHODS 
  SCC samples.     Tumor samples consisted of curetted tumor removed before 
taking the fi  rst Mohs section during Mohs micrographic excision of biopsy-
proven SCCs. Acquisition of tumor samples and all studies were approved 
by the Institutional Review Board of the Dana Farber Cancer Institute and 
were performed in accordance with the Declaration of Helsinki. Tumors 
were divided into bread loaf sections. Adjacent sections were used for (a) 
immunohistochemical or immunofl  uorescence studies to confi  rm the pres-
ence of invasive tumor cells and (b) T cell isolation, as described in the fol-
lowing section. The SCC13 SCC cell line was provided by J. Rheinwald 
(Brigham and Women’s Hospital, Boston, MA). 
  Isolation of T cells from SCC tumors and normal skin.     The clinically 
evident portions of biopsy-proven invasive SCC tumors were obtained. The 
tumors were divided into bread loaf sections. One section was histologically 
examined to confi  rm the presence or absence of invasive SCC tumor. Sec-
tions without evidence of tumor were designated peritumoral. Tumor-infi  l-
trating T cells were isolated from sections adjacent to those studied by 
histology. T cells were isolated from SCC tumors in the absence of exoge-
nous cytokines, as previously described (  28  ). For normal skin studies, T cells 
were isolated from skin discarded after plastic surgery procedures from 3 wk 
explant cultures (  28  ). Skin was provided by T. Cochran (Boston Center for 
Plastic Surgery, Boston, MA) and E. Eriksson (Brigham and Women’s Hos-
pital, Boston, MA). 
  Flow cytometry studies.     Flow cytometry analysis of T cells was performed 
using directly conjugated monoclonal antibodies obtained from: BD Bio-
sciences (CD3, CD4, CD8, CD25, CD69, CD45RO, and IL-10), BD 
PharMingen (CLA, CCR4 [1G], CD73, and CCR6), Abcam (CD39), 
Beckman Coulter (L-selectin), R  &  D Systems (TGF-    , CCR7, and CD127), 
and eBioscience (FOXP3, clone PCH101). Analysis of fl  ow cytometry sam-
ples was performed on Becton Dickinson FACScan or FACSCanto instru-
ments, and data were analyzed using FACSDiva software (V5.1). 
  Immunofl  uorescence  studies.     SCC tumors were embedded in OCT, 
frozen, and stored at     80  °  C until use. 5-  μ  m cryosections were cut, air dried, 
fi  xed for 5 min in acetone, rehydrated in PBS, and blocked with 20   μ  g/ml 
of human IgG (Jackson ImmunoResearch Laboratories) for 15 min at 
room temperature. Sections were incubated with primary antibody for 
30 min, and then rinsed three times in PBS/1% BSA for 5 min. If necessary, 2232 IMMUNE EVASION IN SQUAMOUS CELL CARCINOMAS OF THE SKIN   | Clark et al. 
FOXP3, and analyzed by fl  ow cytometry. Percentage of survival was calcu-
lated as the number of T cells (imiquimod-treated)/(control medium-treated)   ×   
100 for both CD3  +  FOXP3        (non-T reg cell) and CD3  +  FOXP3  +   (T reg 
cell) T cells. To assess the eff  ect on proliferation, T cells from normal human 
skin were labeled with 0.5     M CFSE (Invitrogen) per manufacturer  ’  s direc-
tions and cultured for 1 wk on dermal fi  broblast monolayers and IL-15 
(20 ng/ml; R  &  D Systems) either with or without 3     M imiquimod. T cells 
were stained for CD3 and FOXP3 and analyzed by fl  ow cytometry. For 
regulatory cell functional assays, 3     M imiquimod was added to explant cul-
tures during the last 2  –  5 d before T cell collection, and cells were then har-
vested and assayed for regulatory activity. 
  Functional assays of regulatory T cell activity.     T cells were isolated 
from untreated or imiquimod-treated explant cultures and assayed for regu-
latory T cell functional, as previously described (  20  ). If included, imiquimod 
was present at 3     M concentration. 
  Online supplemental material.     In Fig. S1. FOXP3  +   T reg cells were 
isolated from SCC via explant cultures and stained for surface CD127 and 
nuclear FOXP3 as described in Materials and methods. In Fig. S2, for ex-
pression of CD39 and CD73, imiquimod or control medium was added to 
explant cultures of normal human skin for the last 7 d before T cell iso-
lation. T cells were then collected from explant cultures, stained for surface 
CD39 and CD73 and for nuclear FOXP3, and examined by fl  ow cytometry. 
The online version of this article is available at http://www.jem.org/cgi/
content/full/jem.20071190/DC1. 
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